AU2001280448A1 - Vitamin C Compositions - Google Patents
Vitamin C CompositionsInfo
- Publication number
- AU2001280448A1 AU2001280448A1 AU2001280448A AU2001280448A AU2001280448A1 AU 2001280448 A1 AU2001280448 A1 AU 2001280448A1 AU 2001280448 A AU2001280448 A AU 2001280448A AU 2001280448 A AU2001280448 A AU 2001280448A AU 2001280448 A1 AU2001280448 A1 AU 2001280448A1
- Authority
- AU
- Australia
- Prior art keywords
- vitamin
- compositions
- hydroxy
- composition
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims description 38
- 239000000203 mixture Substances 0.000 title claims description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims description 14
- 229930003268 Vitamin C Natural products 0.000 title claims description 14
- 235000019154 vitamin C Nutrition 0.000 title claims description 14
- 239000011718 vitamin C Substances 0.000 title claims description 14
- 235000010323 ascorbic acid Nutrition 0.000 claims description 10
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- -1 vitamin C compound Chemical class 0.000 claims description 5
- JNVNJZNYIRZKLP-UHFFFAOYSA-N 3,5-dihydroxy-2-(hydroxymethyl)pyran-4-one Chemical compound OCC=1OC=C(O)C(=O)C=1O JNVNJZNYIRZKLP-UHFFFAOYSA-N 0.000 claims description 4
- KTKGSSUXUIUZDA-UHFFFAOYSA-N 4-hydroxy-5-methyloxolan-3-one Chemical compound CC1OCC(=O)C1O KTKGSSUXUIUZDA-UHFFFAOYSA-N 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- DLVYTANECMRFGX-UHFFFAOYSA-N norfuraneol Natural products CC1=C(O)C(=O)CO1 DLVYTANECMRFGX-UHFFFAOYSA-N 0.000 claims description 4
- 229930000044 secondary metabolite Natural products 0.000 claims 3
- 239000000047 product Substances 0.000 description 9
- 150000000994 L-ascorbates Chemical class 0.000 description 3
- 235000010376 calcium ascorbate Nutrition 0.000 description 3
- 229940047036 calcium ascorbate Drugs 0.000 description 3
- 239000011692 calcium ascorbate Substances 0.000 description 3
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SSSNQLHKSUJJTE-UHFFFAOYSA-N 5-Hydroxymaltol Chemical compound CC=1OC=C(O)C(=O)C=1O SSSNQLHKSUJJTE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- VJOGYMFEXBOAPD-UHFFFAOYSA-N 5-hydroxymaltol Natural products OC1=C(OC=C(C1=O)C)C VJOGYMFEXBOAPD-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Description
VITAMIN C COMPOSITIONS
This invention relates to Vitamin C compositions.
More particularly, this invention relates to Vitamin C compositions suitable for preparing finished products such as cosmetic and dermatologic preparations, food products, e.g., processed foods, beverages, and nutritional supplements, and for preparing medicinal, dental, opthalmic and surgical compositions for both enteral and parenteral introduction.
Vitamin C has many known biological functions, e.g., acting as a wound healing accelerant, to prevent or treat periodontal disease, as an enzymatic co-factor,
as a "sparing" agent against vitamin E depletion, as a collagen-synthesis stimulator, etc. Vitamin C is known to counteract oxygen-containing free radicals, including both the superoxide and hydroxyl radicals. These oxidative free radicals are generated in-
vivo under a variety of normal and pathological conditions, and vitamin C is known for its ability to ameliorate conditions caused by oxygen free radicals, e.g., sunburn, cataracts, premature aging and a variety of other degenerative conditions.
The compositions of the invention comprise Vitamin C and a secondary
component which is at least one compound selected from the group consisting of 4- hydroxy-5-methyl-3(2H)-furanone, 3-hydroxy-kojic acid, threose, erythreose, and 5- hydroxymaltol. According to the presently preferred embodiment of the invention,
the Vitamin C component is a mineral ascorbate, i.e., a pharmacologically acceptable salt of ascorbic acid, including salts and complexes of ascorbate anions with
pharmacologically acceptable cations of the alkali elements (sodium, potassium, etc.), alkaline-earth elements (calcium, magnesium, etc.), or transition elements (copper,
iron, zinc, chromium, etc.).
In addition to the normal utility of the Vitamin C component, these
compositions will induce improved dose-dependent, selective apoptosis of diverse human tumor cell-types, even though the concentration of the secondary component in these compositions is very low, i.e., from about .01 to about 1.0% by weight of the total composition.
The mineral ascorbates used in practicing the preferred embodiment of the invention are conveniently available as high-purity commercial products. If a single
mineral ascorbate is used, it is presently preferred to use calcium ascorbate, although it is contemplated that two or even more mineral ascorbates may be employed,
depending upon the end-use product involved.
Although calcium ascorbate is presently preferred, depending on the end-use of the finished products, other pharmacologically acceptable mineral ascorbates,
illustratively, magnesium, sodium, potassium and/or zinc ascorbates and mixtures thereof are effectively employed.
The procedures for preparing the compositions of the invention are not critical
and various modifications of the procedures described below will readily occur to persons skilled in the art having regard for these disclosures, hi general the
components are merely physically admixed and then tableted with tableting excipients, encapsulated or compression molded to provide convenient dosage forms.. Alternatively, the compositions can be prepared as a stable liquid according to the processes disclosed in my issued U.S. Patent 6,197,813.
EXAMPLES
The following examples are presented to aid in understanding the invention and to illustrate the presently preferred practice thereof. As illustrations, they are not intended to limit the scope of the invention, which is defined only by the appended claims.
Example 1
The following components are mixed to provide a composition with the
components in the indicated percent by weight.
Component Wt.%
PRODUCT A calcium ascorbate 95.00
4-hydroxy-5-methyl-3(2H)-furanone 1.00
Other (ascorbic acid, dehydroascorbic acid, etc.) 4.00
PRODUCT B sodium ascorbate 96.5
3-hydroxy-kojic acid 0.2
Other 3.3
Example 2
This example illustrates the preparation of a food product, using the
compositions of the invention, e.g., the compositions of Example 1.
500 ml of dry granulated sugar is added to 125 ml of water and 125 ml of corn syrup and the mixture is stirred and brouglit to boil at 150°C. Heating is discontinued and cherry flavoring is added to taste and desired color. Product A of Example 1 is added in the quantity required to obtain the desired Vitamin C content, e.g., 30 mg Vitamin C/g of "candy" food product. The composition and the sugar-syrup base are thoroughly mixed for sufficient time to fully disperse the concentrate product. Portions of the resulting hot mixture are transferred to the cavities a candy mold and cooled to form a Vitamin C enriched hard candy product.
Having described my invention in such terms as to enable those skilled in the art to understand and practice it and, having identified the presently preferred embodiments thereof, I CLAIM:
Claims (4)
1. A composition, comprising:
(a) a vitamin C compound; and
(b) at least one secondary compound selected from the group consisting of 4-hydroxy-5-methyl-3(2H)-furanone and 3- hydroxy-kojic acid.
2. The composition of Claim 1 wherein said vitamin C compound is a mineral ascorbate.
3. The composition of Claim 2 wherein said secondary compound is 4-hydroxy-5-methyl-3(2H)-furanone.
4. The composition of Claim 2 wherein said secondary compound is 3- hydroxy-kojic acid.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/000233 WO1998032115A1 (en) | 1997-01-20 | 1998-01-05 | Devices for mounting and display of electronic labels and the like |
| US98/02333 | 1998-02-06 | ||
| PCT/US1999/002735 WO1999039580A1 (en) | 1998-02-06 | 1999-02-05 | Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| PCT/US2001/020431 WO2003002113A1 (en) | 2001-06-26 | 2001-06-26 | Vitamin c compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU26647/99A Division AU744584B2 (en) | 1998-02-06 | 1999-02-05 | Stable liquid mineral ascorbate compositions and methods of manufacture and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2001280448A1 true AU2001280448A1 (en) | 2003-05-15 |
| AU2001280448B2 AU2001280448B2 (en) | 2007-12-06 |
| AU2001280448B8 AU2001280448B8 (en) | 2008-05-29 |
Family
ID=39488228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001280448A Expired AU2001280448B8 (en) | 1998-01-05 | 2001-06-26 | Vitamin C Compositions |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2001280448B8 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999039580A1 (en) * | 1998-02-06 | 1999-08-12 | Oxycal Laboratories, Inc. | Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| NZ511396A (en) * | 1999-08-30 | 2003-08-29 | Oxycal Lab Inc | Compositions containing a metal salt of ascorbic acid for selective cancer chemotherapy |
-
2001
- 2001-06-26 AU AU2001280448A patent/AU2001280448B8/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100373393B1 (en) | Tablet-type Vitamin and Calcium Complex Therapeutic Agents as Unit Herbal Medicine Agents and Their Preparation and Uses | |
| KR100421466B1 (en) | Manufacturing Method of Absorptive Zinc-Oligopeptide in The Human Body | |
| CA2281054C (en) | Combination of zinc ions and vitamin c and method of making | |
| AU1761492A (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| CA2211177C (en) | Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates | |
| KR20040106367A (en) | Difructose anhydride-containing composition and use thereof | |
| EP3247323B1 (en) | Chlorophyll composition | |
| US6878744B2 (en) | Vitamin C compositions | |
| EP4181693A1 (en) | Nutritional supplement, suitable for oral administration, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity, for use in the maintenance of normal liver function | |
| AU2001280448B8 (en) | Vitamin C Compositions | |
| AU2001280448A1 (en) | Vitamin C Compositions | |
| WO2003002113A1 (en) | Vitamin c compositions | |
| KR102590017B1 (en) | Composition for improving oral condition | |
| US5948824A (en) | Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents | |
| JP3250071B2 (en) | Anti-osteoporosis composition | |
| JPH0998738A (en) | Easily absorbable calcium composition | |
| WO2008015535A2 (en) | Composition with improved antioxidant and antiglycating activity | |
| JPH08268882A (en) | Lipase inhibitor | |
| JP2003063970A (en) | Anti-osteoporosis composition | |
| KR20110057480A (en) | Vitamin Tablets Containing Vitamin C Mixture | |
| JP3495085B2 (en) | Active oxygen scavenger and composition containing the same | |
| JP2006519859A (en) | Bicarbonate and potassium ascorbate taurate complex | |
| CN118141111A (en) | A composition for prolonging life, and its preparation method and application | |
| MX2007002463A (en) | Preparation comprising ionic iron and haem iron and variants thereof for the prophylaxis and treatment of iron deficiency. |